These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR. J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541 [Abstract] [Full Text] [Related]
4. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ. Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448 [Abstract] [Full Text] [Related]
5. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. Pearson DA, Lister-James J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Taylor JE, Moyer BR, Dean RT. J Med Chem; 1996 Mar 29; 39(7):1361-71. PubMed ID: 8691466 [Abstract] [Full Text] [Related]
6. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Cancer Res; 1998 May 01; 58(9):1850-9. PubMed ID: 9581824 [Abstract] [Full Text] [Related]
7. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors. Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi SE. Nucl Med Biol; 2007 Aug 01; 34(6):651-7. PubMed ID: 17707805 [Abstract] [Full Text] [Related]
8. In vitro and in vivo evaluation of copper-64-octreotide conjugates. Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ. J Nucl Med; 1995 Dec 01; 36(12):2315-25. PubMed ID: 8523125 [Abstract] [Full Text] [Related]
9. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Eur J Nucl Med Mol Imaging; 2005 Nov 01; 32(11):1288-95. PubMed ID: 16021448 [Abstract] [Full Text] [Related]
10. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation. De K, Banerjee I, Misra M. Amino Acids; 2015 Jun 01; 47(6):1135-53. PubMed ID: 25743164 [Abstract] [Full Text] [Related]
11. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, Cordopatis P, Chiotellis E. Eur J Nucl Med Mol Imaging; 2002 Jun 01; 29(6):742-53. PubMed ID: 12029547 [Abstract] [Full Text] [Related]
12. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. Eur J Nucl Med Mol Imaging; 2003 Oct 01; 30(10):1338-47. PubMed ID: 12937948 [Abstract] [Full Text] [Related]
13. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. J Med Chem; 1999 Apr 22; 42(8):1341-7. PubMed ID: 10212119 [Abstract] [Full Text] [Related]
15. Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging. Erfani M, Shafiei M, Mazidi M, Goudarzi M. Cancer Biother Radiopharm; 2013 Apr 22; 28(3):240-7. PubMed ID: 23464855 [Abstract] [Full Text] [Related]
16. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease. Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, Thaler A, Wedrich A, Virgolini I. J Nucl Med; 2003 Oct 22; 44(10):1547-55. PubMed ID: 14530465 [Abstract] [Full Text] [Related]
17. 99mTc targeting of Sst2-expressing tumors by tetraamineoctreotide: first results in CA20948 cells and rat models. Nikolopoulou A, Nock BA, Maina T. Anticancer Res; 2006 Oct 22; 26(1A):363-6. PubMed ID: 16475719 [Abstract] [Full Text] [Related]
19. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, Srinivasan A, Schmidt M, Krenning EP. J Nucl Med; 1999 Dec 22; 40(12):2081-7. PubMed ID: 10616889 [Abstract] [Full Text] [Related]